EUCTR2006-001245-33-BE进行中（未招募）不适用
Double-blind, randomised, placebo-controlled, phase III study comparing the efficacy and safety of bilastine 20 mg once daily and levocetirizine 5 mg for the treatment of chronic idiopathic urticaria.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 540
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients of either sex between 18 and 70 years of age.
- •Patients with a documented history of chronic idiopathic urticaria for at least 6 weeks prior to entry in the study, characterized by erythematous skin wheals accompanied by itching, occurring regularly, at least 3 times per week.
- •Subjects who have given their informed consent to participate in the study after having received information about the design, aims and potential risks that could result from the study and having been informed that they can refuse to take part in or withdraw from the study at any time.
- •Patients with active chronic idiopathic urticaria in the week before randomization visit (D-7), and at the randomization visit (D0). Patients should have for at least 3 days (consecutive or not) a moderate score (> 2) for at least 2 of the following symptoms.
- •-Itching intensity 0 = Absent, 1 = Mild (not annoying), 2 = Moderate (little disruption of activity), 3 = Severe (intense with disruption of activity)
- •-Wheals number 0 = Absent, 1 = Some (< 10), 2 = Numerous (>10), 3 = Extensive areas of the body covered
- •-Maximum size of the wheals 0 = Absent, 1 = < 1’5 cm, 2 = > 1’5 cm y < 2’5 cm, 3 = = 2’5 cm
- •Patients willing to attend the required visits scheduled in the protocol, and fill in the diary card provided.
- •Patients must undergo a medical examination to participate in the study, and it should be normal.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients meeting any of the following criteria may not be enrolled in this study:
- •Patients that suffered other kind of dermatological pathology that can interfere in the evaluation of the chronic idiopathic urticaria: (isolated hereditary angioedema, dermographism, physics urticaria, urticaria due to a medicine or food allergy, infectious urticaria, contact urticaria, urticaria caused by vasculitis and/or colagenosis, paraneoplasic urticaria, parasitary urticaria, urticaria related with thyroid pathology, eczema or athopic dermatitis.
- •Patients who have a history of autoimmune disorders, Hodgkin’s disease, lymphoma, leukemia and generalized cancer.
- •Patients who are taking or have taken any of the following medications prior to enrolment in the study and have not complied with the specified wash-out period: Note: These wash-out periods should refer to the randomisation date.
- •- Systemic or topical corticosteroids: 4 weeks.
- •- Antihistamines: Astemizole (6 weeks), loratadine and desloratadine (10 days), other systemic antihistamines (3 days).
- •- Anti-leukotrienes (3 days)
- •- Doxepine (10 days)
- •- Delayed-release corticosteroids (3 months).
- •- Ketotifen (2 weeks).
- •- Tricyclic antidepressants (1 week)
- •- Macrolides antibiotics and imidazolic antifungals (systemic)
- •- H2 antihistamines.
- •- Anticholinergics.
- •- Drugs with antihistamine properties (phenothiazine).
- •- Sodium chromoglycate, nedocromil. (2 weeks).
- •- and any other drug with sedating action, anxiolytics, hypnotics, opioids, neuroleptics.
- •For those treatments with no wash-out period in brackets, the interruption of the treatment at the randomization visit is allowed.
- •Hypersensitivity to H1 antihistamines, benzimidazoles or lactose.
- •Severe concomitant disease that could interfere with treatment response (hepatic, renal, cardiovascular), electrocardiographic abnormalities, arrhythmias, recent acute myocardial infarction or neoplastic diseases.
- •Pregnant or breast-feeding women. Women who could potentially become pregnant must use an effective birth control method (oral contraceptives, intrauterine device, condom or diaphragm). The patient’s agreement to use it will be considered sufficient for participation in the study.
- •Before the randomization a urine pregnancy test will be conducted in women with childbearing potential.
- •Patients who will be operating heavy machinery or need to drive motor vehicles as an essential part of their profession.
- •Patients with a mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study or patients unable to sign the informed consent form
- •Patients unable to comply with the study requirements or unable to complete the patient diary and take the study treatment.
- •Patients who have a known lack of response to H1-antihistamines.
- •Patients who have a recent history (within previous 12 months) of drug addiction or alcohol abuse.
- •Patients whose health could be harmed by their participation in the study.
- •Patients who are currently participating in or have participated in another clinical trial within the last three months.
- •Any waiver of these inclusion and exclusion criteria must be approved by the investigator and the Sponsor (or its representative) on a case-by case basis prior to enrolling the subject. This must be documented by both the Sponsor and the investigator.
研究者
相似试验
进行中（未招募）
1 期
Clinical study comparing two doses of norucholic acid against placebo in the treatment of a liver disease called primary biliary cholangitis in patients without sufficient response to ursodeoxycholic acidprimary biliary cholangitisMedDRA version: 27.0Level: PTClassification code 10080429Term: Primary biliary cholangitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2021-001431-56-NODr. Falk Pharma GmbH90
进行中（未招募）
1 期
Clinical trial comparing the efficacy and safety of norursodeoxycholic acid tablets with placebo in the treatment of non-alcholic fatty liver disease with liver inflammation (non-alcoholic steatohepatitis[NASH])on-alcoholic steatohepatitis (NASH)MedDRA version: 24.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2018-003443-31-HUDr. Falk Pharma GmbH363
进行中（未招募）
1 期
Clinical study comparing two doses of norucholic acid against placebo in the treatment of a liver disease called primary biliary cholangitis in patients without sufficient response to ursodeoxycholic acidEUCTR2021-001431-56-ATDr. Falk Pharma GmbH90
进行中（未招募）
1 期
Clinical trial comparing the efficacy and safety of Rhudex granules with placebo in the treatment of the liver disease Primary Biliary CholangitisPrimary biliary cholangitisMedDRA version: 21.0Level: PTClassification code 10080429Term: Primary biliary cholangitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2020-001961-34-BEDr. Falk Pharma GmbH136
进行中（未招募）
不适用
Double-blind, randomised, placebo-controlled, phase III study comparing the efficacy and safety of bilastine 20 mg once daily and cetirizine 10 mg for the treatment of allergic allergic rhinitisEUCTR2004-004586-14-BEFAES FARMA S.A.790